Home > Journals > The Quarterly Journal of Nuclear Medicine and Molecular Imaging > Past Issues > The Quarterly Journal of Nuclear Medicine and Molecular Imaging 2015 September;59(3) > The Quarterly Journal of Nuclear Medicine and Molecular Imaging 2015 September;59(3):241-68

CURRENT ISSUE
 

ARTICLE TOOLS

Reprints

THE QUARTERLY JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING

A Journal on Nuclear Medicine and Molecular Imaging


A Journal on Nuclear Medicine and Molecular Imaging
Affiliated to the Society of Radiopharmaceutical Sciences and to the International Research Group of Immunoscintigraphy
Indexed/Abstracted in: Current Contents/Clinical Medicine, EMBASE, PubMed/MEDLINE, Science Citation Index (SciSearch), Scopus
Impact Factor 2,481


eTOC

 

REVIEWS  RADIOPHARMACOLOGY - RECENT DEVELOPMENTS IN THE FIELD OF RADIOPHARMACEUTICALSFREEfree


The Quarterly Journal of Nuclear Medicine and Molecular Imaging 2015 September;59(3):241-68

Copyright © 2015 EDIZIONI MINERVA MEDICA

language: English

Prostate-specific membrane antigen as a target for cancer imaging and therapy

Kiess A. P. 1, Banerjee S. R. 2, Mease R. C. 2, Rowe S. P. 2, Rao A. 1, Foss C. A. 2, Chen Y. 2, Yang X. 2, Cho S. Y. 3, Nimmagadda S. 2, Pomper M. G. 1, 2

1 Department of Radiation Oncology, Johns Hopkins Medical Institutions, Baltimore, MD, USA; 2 The Russell H. Morgan Department of Radiology and Radiological Science, Johns Hopkins Medical Institutions, Baltimore, MD, USA; 3 Department of Radiology, University of Wisconsin School of Medicine and Public Health, Madison, WI, USA


FULL TEXT  


The prostate-specific membrane antigen (PSMA) is a molecular target whose use has resulted in some of the most productive work toward imaging and treating prostate cancer over the past two decades. A wide variety of imaging agents extending from intact antibodies to low-molecular-weight compounds permeate the literature. In parallel there is a rapidly expanding pool of antibody-drug conjugates, radiopharmaceutical therapeutics, small-molecule drug conjugates, theranostics and nanomedicines targeting PSMA. Such productivity is motivated by the abundant expression of PSMA on the surface of prostate cancer cells and within the neovasculature of other solid tumors, with limited expression in most normal tissues. Animating the field is a variety of small-molecule scaffolds upon which the radionuclides, drugs, MR-detectable species and nanoparticles can be placed with relative ease. Among those, the urea-based agents have been most extensively leveraged, with expanding clinical use for detection and more recently for radiopharmaceutical therapy of prostate cancer, with surprisingly little toxicity. PSMA imaging of other cancers is also appearing in the clinical literature, and may overtake FDG for certain indications. Targeting PSMA may provide a viable alternative or first-line approach to managing prostate and other cancers.

top of page

Publication History

Cite this article as

Corresponding author e-mail

mpomper@jhmi.edu